Dyadic International (DYAI) EBITDA Margin (2018 - 2026)
Dyadic International's (DYAI) quarterly EBITDA Margin came in at 171.27% in Q1 2026, up 33753.0% year-over-year from N/an in Q1 2025, and up 36.94% quarter-over-quarter from 271.59% in Q4 2025.
Analysis
Dyadic International (DYAI) EBITDA Margin (2018 - 2026) Analysis & Trends
Dyadic International has disclosed EBITDA Margin across 9 years of filings, most recently posting 171.27% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 33753.0% year-over-year to 171.27%; the TTM figure through Mar 2026 stood at 186.28% (down 2373.0% YoY), while the FY2025 annual figure was 232.75%, down 6393.0% from the prior year.
- EBITDA Margin came in at 171.27% for Q1 2026 at Dyadic International, up from 271.59% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 10.35% in Q3 2024 to a low of 635.22% in Q1 2024.
- Average EBITDA Margin over 5 years is 313.55%, with a median of 273.6% recorded in 2023.
- Year-over-year, EBITDA Margin surged 104452 bps in 2022 and plunged 42557 bps in 2024.
- Over 5 years, EBITDA Margin stood at 301.13% in 2022, then decreased by 5 bps to 315.89% in 2023, then jumped by 41 bps to 187.19% in 2024, then sank by 45 bps to 271.59% in 2025, then surged by 37 bps to 171.27% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 171.27% in Q1 2026, 271.59% in Q4 2025, and 165.32% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Dyadic International | 17.78 Mn | 9.82 Mn | - | -171.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -171.27% |
| Dec 31, 2025 | -271.59% |
| Sep 30, 2025 | -165.32% |
| Jun 30, 2025 | -178.88% |
| Mar 31, 2025 | -508.80% |
| Dec 31, 2024 | -187.19% |
| Sep 30, 2024 | -10.35% |
| Jun 30, 2024 | -529.31% |
| Mar 31, 2024 | -635.22% |
| Dec 31, 2023 | -315.89% |
| Sep 30, 2023 | -433.21% |
| Jun 30, 2023 | -273.60% |
| Mar 31, 2023 | -209.65% |
| Dec 31, 2022 | -301.13% |
| Sep 30, 2022 | -211.86% |
| Jun 30, 2022 | -503.83% |
| Mar 31, 2022 | -423.28% |
| Dec 31, 2021 | -1,345.65% |
| Sep 30, 2021 | -479.70% |
| Jun 30, 2021 | -412.67% |